Eton Pharmaceuticals (NASDAQ:ETON) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Eton Pharmaceuticals (NASDAQ:ETON) from a hold rating to a buy rating in a research note published on Wednesday, ValuEngine reports.

A number of other equities analysts also recently issued reports on ETON. HC Wainwright reissued a buy rating and issued a $21.00 price objective (up previously from $18.00) on shares of Eton Pharmaceuticals in a report on Wednesday, October 23rd. Zacks Investment Research cut shares of Eton Pharmaceuticals from a hold rating to a sell rating in a report on Friday, November 22nd. Finally, B. Riley began coverage on shares of Eton Pharmaceuticals in a research report on Friday, September 20th. They issued a buy rating and a $13.50 price target on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $13.75.

ETON stock opened at $5.97 on Wednesday. The business’s 50-day moving average is $6.02 and its two-hundred day moving average is $6.59. Eton Pharmaceuticals has a fifty-two week low of $5.13 and a fifty-two week high of $10.20.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings results on Thursday, November 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.05). On average, equities analysts predict that Eton Pharmaceuticals will post -1.13 earnings per share for the current year.

Large investors have recently bought and sold shares of the company. BlackRock Inc. raised its holdings in Eton Pharmaceuticals by 181.2% in the 2nd quarter. BlackRock Inc. now owns 26,092 shares of the company’s stock worth $206,000 after purchasing an additional 16,813 shares during the period. Vanguard Group Inc. increased its position in Eton Pharmaceuticals by 6.7% in the second quarter. Vanguard Group Inc. now owns 28,762 shares of the company’s stock worth $227,000 after buying an additional 1,800 shares in the last quarter. First Allied Advisory Services Inc. bought a new position in shares of Eton Pharmaceuticals in the third quarter worth about $228,000. First Trust Advisors LP bought a new position in shares of Eton Pharmaceuticals in the third quarter worth about $155,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Eton Pharmaceuticals by 122.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,139 shares of the company’s stock worth $25,000 after buying an additional 1,728 shares during the period. Hedge funds and other institutional investors own 12.80% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.

Featured Story: Dogs of the Dow

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit